How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?

DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.

Answer from: Medical Oncologist at Academic Institution

With the publication of the SWOG Cancer Research Network's collaboration with the National Clinical Trials Network, Protocol S1826 results allow a definitive recommendation of nivolimab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) as the treatment of choice for this patient.

Comments

Medical Oncologist at University of Michigan
The SWOG trial enrolled stage III or IV classical ...

Medical Oncologist at University of Kansas Cancer Center
Would recommend this regimen of BV + AVD x 4 in su...

Please select the option that best describes you:

How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?

Related Questions